摘要
目的探讨同步放化疗治疗Ⅲ期非小细胞肺癌(NSCLC)的近期疗效、不良反应及可行性。方法对28例ⅢA和ⅢB期NSCLC患者,采用多西紫杉醇联合顺铂的化疗方案,其中多西紫杉醇为35mg/m2、顺铂25mg/m2,于放疗的第1天开始,每周1次,连续进行,每周复查血常规和肝功能;放疗结束14天后继续化疗,多西紫杉醇95mg/m2第1天,顺铂75mg/m2分3天给予,第1、2、3天。放疗采用三维适形放疗,胸部照射2Gy/次,5次/周,共6～7周,中位剂量为60Gy。结果总有效率为78.6%(22/28),1、2、3年生存率分别为57.1%(16/28)、35.7%(10/28)和17.8%(5/28),中位生存期为11.6～22个月。结论对Ⅲ期非小细胞肺癌,采用同步放化疗治疗可获得较好的近期疗效和1、2、3年生存率,不良反应可以耐受,值得临床推广。
Objective To evaluate the efficacy, toxicities and feasibility of concurrent chemo - radiotherapy for patients with stage Ⅲ non - small cell lung cancer （NSCLC）. Methods 28 patients with stage Ⅲ A and Ⅲ B NSCLC were treated by chemo - radiotherapy. 3-D conformal radiotherapy was given to all patients in 2 Gy per fraction in 6 to 7 weeks to total doses of 60 Gy. Chemotherapy including docetaxel 35 mg/m^2 and cisplatin 35 mg/m2 was given concurrently to radiotherapy from the first day of radiotherapy and repeated every week. 14 days after the completion of concurrent treatment, the patients received adjuvant chemotherapy of docetaxe195 mg/m2 and cisplatin 75 mg/m2. Results The overall response rate was 78.6% （22/28） ; and 1,2, 3 -year survival rate was 57.1% （16/28） ,35.7% （10/28） and 17.8% （5/28）. The median survival time was from 11.6 months to 22 months. Conclusion The short - term result was promising in patients with stage Ⅲ non - small cell lung cancer treated by concurrent chemo -radiotherapy.
出处
《实用癌症杂志》
2010年第2期158-160,共3页
The Practical Journal of Cancer
关键词
非小细胞肺癌
三维适形放射治疗
化学疗法
同步放化疗
Non-small cell lung cancer （ NSCLC ）
3D-CRT
Chemotherapy
Concurrent chemo-rediotherapy
